Filing Details

Accession Number:
0001104659-22-084894
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-01 21:01:07
Reporting Period:
2022-08-01
Accepted Time:
2022-08-01 21:01:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1621227 Adaptimmune Therapeutics Plc ADAP Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1784487 John Lunger C/O Adaptimmune Therapeutics Plc,
60 Jubilee Avenue, Milton Park
Abingdon X0 OX14 4RX
Chief Patient Supply Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Representing Ordinary Shares Disposition 2022-08-01 2,983 $1.77 4,829 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.7642 to $1.7808, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
  3. The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 55,428 ADSs and RSU-style options and other options covering an aggregate of 6,225,276 ordinary shares of the Issuer.